HC Wainwright reiterated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for Unity Biotechnology’s Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.49) EPS, FY2025 earnings at ($1.71) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.75 EPS.
Unity Biotechnology Stock Performance
Shares of NASDAQ:UBX opened at $1.44 on Thursday. The stock has a market capitalization of $24.18 million, a price-to-earnings ratio of -0.57 and a beta of 0.84. Unity Biotechnology has a 1-year low of $1.22 and a 1-year high of $2.67. The company has a 50 day moving average price of $1.45 and a 200 day moving average price of $1.56.
Unity Biotechnology (NASDAQ:UBX – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.15. On average, sell-side analysts expect that Unity Biotechnology will post -1.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Unity Biotechnology
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
See Also
- Five stocks we like better than Unity Biotechnology
- The Significance of Brokerage Rankings in Stock Selection
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- What are earnings reports?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.